We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
RNA biotech Skyhawk Therapeutics is inking another R&D deal—this time, it’s with Takeda Pharmaceutical, which wants to use the biotech’s platform to develop small molecules that correct RNA mis-splicing in neurodegenerative disease.